LD
Therapeutic Areas
Acerta Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Acalabrutinib (CALQUENCE) | B-cell malignancies (e.g., CLL, MCL, SLL) | Approved/Commercial |
| Pipeline combinations & novel agents | Haematological malignancies | Various (Pre-clinical to Phase 3) |